Abstract:
The present invention relates to a composition useful for hepatoprotection, said composition comprising polar extract of plant Cryptolepis Buchanani and/or fractions of the said extract, and optionally pharmaceutically acceptable additives and a method of producing said composition and also a method of treating a subject using said composition.
Abstract:
An improved and industrially advantageous process for the preparation of the antidepressant fluoxetine and its pharmaceutically acceptable salts, preferably hydrochloride.
Abstract:
The present invention relates to a novel oligospirostanoside having the structure 3-0-[&agr;-L-rhamnopyranosyl-(1→2)-&agr;-L-rhamnopyranosyl-(1→4)-0-&bgr;-D-glucopyranosyl]-25(S)-5&bgr;-spirostan-3&bgr;-ol isolated from Asparagus racemosus and to a pharmaceutical composition containing the novel oligospirostanoside and to a method for immunomodulation using said oligospirostanoside by administering a pharmaceutically effective amount of said novel oligospirostanoside.
Abstract:
An improved method for preparing 2-chlorosulfinyl azetidine-4-one comprises heating a penicillin sulfoxide ester with an N-chlorohalogenating agent at a temperature of about 75.degree. C. to about 140.degree. in an inert organic solvent, and in the presence of an organic solvent insoluble, strongly basic ion exchange resin. Desirably, the ion exchange resin comprises a styrene-divinyl benzane copolymer which is about 2 to 16% cross-linked and incorporates a quaternary ammonium functionality. Such ion exchange resins are commercially available. The 2-chlorosulfinyl azetidine-4-one which is produced by this method can be cyclized in the presence of a Friedel-Crafts catalysts to afford the 3-exomethylene cepham sulfoxide ester in yields of 80-90%.
Abstract:
A computerized method comprising: providing a SaaS-based Platform that provides a DevOPS enabled framework to implement an end to end orchestration of a complex multi-vendor network solution on cloud-computing infrastructure, wherein the SaaS-based platform comprises an orchestrator engine and a deployer module, and wherein the deployer module provides a means to do a one touch deployment of a set of virtual test-beds in a computer network and the cloud-computing infrastructure; installing and configuring a database and queue in each of a plurality of nodes of the computer network; installing and configuring a backend server in each of another plurality of nodes of the computer network; installing and configuring a frontend server in each the other plurality of nodes of the computer network; and installing a service load balancer and configuring each of the set of frontend servers as a backend server.
Abstract:
The invention provides small molecule modulators of retinoic acid receptor-related orphan receptors such as RORα, RORβ, or RORγ. Compounds of the invention can be effective modulators at concentrations ineffective to act on LXR receptors, or on other nuclear receptors, or other biological targets. Methods of modulation the RORs and methods of treating metabolic disorders, immune disorders, cancer, and CNS disorders wherein modulation of an ROR is medically indicated are also provided.
Abstract:
An embodiment of the present invention provides a system and method for remotely upgrading the firmware of a target device using wireless technology from the Bluetooth-enabled PC or Laptop to another Bluetooth device e.g., mouse, Keyboard, headset, mobile phone etc. Existing solutions either may not have upgrade capabilities, or may require the use of proprietary cables. An embodiment of the solution proposed here extends the “Connecting without cables” concept of Bluetooth to firmware upgrades. The system comprises a host device for sending the firmware required for upgradation; and a target device containing a first code and a second code wherein said first code identifies details of the firmware; and said second code identifies the completion of the download operation when the firmware is successfully downloaded.
Abstract:
Compounds of Formula (I), wherein represents a single bond when G is —OH and double bond when G is —O; R1 and R2 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, aralkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, heterocyclylalkyl or heteroarylalkyl; R3 is selected from the group selected from hydrogen, hydroxy, alkoxy, alkenyloxy or alkynyloxy; X is selected from oxygen, —NH, —NR (wherein R is alkyl, alkenyl, alkenyl, alkynyl or aryl), sulphur or no atom; Het is heterocyclyl or heteroaryl; n is an integer from 1 to 6; are muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and 4 i gastrointestinal systems mediated through muscarinic receptors.
Abstract translation:式(I)的化合物,当G为-OH时,当G为-O时,表示单键; R 1和R 2独立地选自氢,烷基,烯基,炔基,芳烷基,环烷基,芳基,杂芳基,杂环基,杂环基烷基或杂芳基烷基; R3选自氢,羟基,烷氧基,烯氧基或炔氧基; X选自氧,-NH,-NR(其中R是烷基,烯基,烯基,炔基或芳基),硫或无原子; Het是杂环基或杂芳基; n是1至6的整数; 是毒蕈碱受体拮抗剂,其可用于治疗通过毒蕈碱受体介导的呼吸,尿和4I胃肠系统的各种疾病,以及其它用途。
Abstract:
The present invention generally relates to muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The present invention also relates to processes for preparing compounds described herein, pharmaceutical compositions thereof, and methods for treating diseases mediated through muscarinic receptors. Formula (I) or a pharmaceutically accepted salt, pharmaceutically acceptable solvate, enantiomers, diastereomer, polymorph or N-oxide thereof, wherein X is.